Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm BvfiledCriticalSolvay Pharm Bv
Publication of AR061193A1publicationCriticalpatent/AR061193A1/es
C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D231/18—One oxygen or sulfur atom
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
ARP070102278A2006-05-312007-05-28Derivados de pirazol que contienen azufre como antagonistas selectivos del receptor cannabinoide cb1
AR061193A1
(es)
Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
Derivater af 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl-phosphonsyre og deres avendelse som n-methyl-D-aspartat (NMDA)-receptor-antagonister